Thomas Charles Reilly
CIK 1827590 · EVP and CFO · last filed 2024-07-01
Thomas Charles Reilly is an EVP and CFO who has filed 16 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for AMRN, was dated Jul 1, 2024. Across all open-market trades the lifetime net is −$51.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.44M
2
16
-$51.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMRN | EVP and CFO | 94,305 | $15.24 | $1.44M | $0 | 10 | 2024-07-01 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | Chief Financial Officer | 37,811 | $15.96 | $603.5K | -$51.4K | 6 | 2022-03-04 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-01 | AMRN | Mixed | +8,458 | -$5.7K | EDGAR |
| 2024-06-21 | AMRN | Mixed | +16,916 | -$12.0K | EDGAR |
| 2024-02-09 | AMRN | Grant (A) | — | $0 | EDGAR |
| 2024-02-02 | AMRN | Mixed | +20,381 | -$30.4K | EDGAR |
| 2024-01-12 | AMRN | Mixed | +23,175 | -$27.5K | EDGAR |
| 2023-07-21 | AMRN | Grant (A) | — | $0 | EDGAR |
| 2023-07-05 | AMRN | Mixed | +8,458 | -$9.8K | EDGAR |
| 2023-06-22 | AMRN | Mixed | +16,917 | -$19.5K | EDGAR |
| 2023-02-23 | AMRN | Grant (A) | — | $0 | EDGAR |
| 2022-07-06 | AMRN | Grant (A) | — | $0 | EDGAR |